Jean-Jacques Garaud, MD Global Head Pharma ... - Roche
Jean-Jacques Garaud, MD Global Head Pharma ... - Roche
Jean-Jacques Garaud, MD Global Head Pharma ... - Roche
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Oncology: Major newsflow expected in H2 2008<br />
MabThera in relapsed CLL: REACH<br />
Randomized ph. III, 552 patients<br />
Fludarabine+cyclophosphamide<br />
+/-MabThera<br />
Avastin in 1st line mBC: RIBBON-1<br />
Phase III study, 1200 patients, 2 analyses:<br />
Anthracycline-/taxane-based +/- Avastin,<br />
and Xeloda +/- Avastin<br />
Expect data H2 ‘08<br />
Expect topline data H2 ‘08<br />
Tarceva+Avastin in 2nd line NSCLC:<br />
BETA lung<br />
Tarceva+/-Avastin<br />
Enrollment completed Q2 ’08<br />
Potentially label-enabling for Avastin<br />
Expect topline data H2 ‘08<br />
Tarceva 1st line maintenance NSCLC:<br />
SATURN<br />
4 chemo cycles followed by T vs. placebo<br />
Enrollment completed Q2 ‘08<br />
Potentially label-enabling for Tarceva<br />
Expect topline data H2 ‘08<br />
22
Change language